Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [31] Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Final Results
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 2 - 4
  • [32] A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
    Barr, Paul M.
    Hill, Brian T.
    Ma, Shuo
    Baran, Andrea M.
    Bui, Andrew
    Meacham, Philip J.
    Morrison, Ashley
    Liesveld, Jane L.
    Mulford, Deborah A.
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Friedberg, Jonathan W.
    Zent, Clive S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 9 - 10
  • [33] Final Results of a Phase 1/2 Study of SYK Inhibitor Entospletinib in Combination with Obinutuzumab in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Danilov, Alexey V.
    Lam, Vi
    Bria, Thurlow
    Spurgeon, Stephen E.
    Park, Byung
    Orand, Kirsten
    Kittai, Adam S.
    BLOOD, 2021, 138
  • [34] A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 19 - 20
  • [35] Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study
    Awan, Farrukh T.
    Thirman, Michael J.
    Patel-Donnelly, Dipti
    Assouline, Sarit
    Rao, Arati, V
    Ye, Wei
    Hill, Brian
    Sharman, Jeff P.
    LEUKEMIA & LYMPHOMA, 2019, 60 (08) : 1972 - 1977
  • [36] Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
    Chanan-Khan, Asher
    Miller, Kena C.
    Musial, Laurie
    Lawrence, David
    Padmanabhan, Swaminathan
    Takeshita, Kenichi
    Porter, Carl W.
    Goodrich, David W.
    Bernstein, Zale P.
    Wallace, Paul
    Spaner, David
    Mohr, Alice
    Byrne, Catriona
    Hernandez-Ilizaliturri, Francisco
    Chrystal, Cynthia
    Starostik, Petr
    Czuczman, Myron S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5343 - 5349
  • [37] Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
    Chavez, Julio C.
    Piris-Villaespesa, Miguel
    Dalia, Samir
    Powers, John
    Turba, Elyce
    Nodzon, Lisa
    Komrokji, Rami
    Sokol, Lubomir
    Locke, Frederick L.
    Lancet, Jeffrey
    Sotomayor, Eduardo M.
    Kharfan-Dabaja, Mohamed A.
    Pinilla-Ibarz, Javier
    LEUKEMIA RESEARCH, 2016, 47 : 78 - 83
  • [38] Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6-year follow-up of CHRONOS-1
    Dreyling, M.
    Santoro, A.
    Mollica, L.
    Leppa, S.
    Follows, G.
    Lenz, G.
    Kim, W. S.
    Nagler, A.
    Panayiotidis, P.
    Ozcan, M.
    Kosinova, M.
    Provencio, M.
    Magagnoli, M.
    Bouabdallah, K.
    Diong, C. Phipps
    Munoz, J.
    Cao, A.
    Hiemeyer, F.
    Odongo, F.
    Garcia-Vargas, J.
    Childs, B.
    Zinzani, P. L.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 51 - 52
  • [39] Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Byrd, John C.
    Furman, Richard R.
    Coutre, Steven
    Flinn, Ian W.
    Burger, Jan A.
    Blum, Kristie A.
    Sharman, Jeff
    Wierda, William G.
    Zhao, Weiqiang
    Heerema, Nyla A.
    Luan, Ying
    Liu, Emily A.
    Dean, James P.
    O'Brien, Susan M.
    BLOOD, 2018, 132
  • [40] A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Barr, Paul M.
    Hill, Brian T.
    Ma, Shuo
    Baran, Andrea M.
    Bui, Andrew
    Meacham, Philip J.
    Morrison, Ashley
    Liesveld, Jane L.
    Mulford, Deborah A.
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Friedberg, Jonathan W.
    Zent, Clive S.
    BLOOD, 2019, 134
12345